MAPKAPK2 and periodontal disorder: As periodontal disease has remarkably similar inflammatory pathways and mediator profiles with other inflammatory diseases [6, 127, 128], it is reasonable to anticipate that MK2 would be an attractive and potentially selective target for the treatment of periodontitis.